Histone cluster 1 H2BH activators would constitute a class of chemical agents that target and interact with the H2BH variant of histone proteins. Histones are integral to the formation of nucleosomes, the building blocks of chromatin, which in turn is central to the organization of DNA within the nucleus of eukaryotic cells. The H2BH variant is a specialized member of the H2B family of histones and is likely to impart specific structural or functional characteristics to nucleosomes due to its unique sequence or conformational distinctions. Activators in this class would be designed to selectively bind to the H2BH histone variant, with the intention of modifying its interaction with DNA or with other histone proteins. By influencing H2BH, these activators could alter nucleosome stability and affect chromatin compaction, which in turn could modulate the accessibility of DNA to various proteins involved in DNA transcription, replication, and repair. These activators would need to be highly specific to H2BH to avoid off-target effects on other histone proteins, ensuring the precise modulation of chromatin structure.
The development of H2BH activators would require a detailed molecular understanding of this particular histone variant, including its role in the nucleosome and its contribution to the overall architecture of chromatin. This would involve identifying the unique amino acid sequences and structural domains of H2BH that could be targeted by such activators. These unique features could serve as potential binding sites for small molecules, peptides, or other biologically active compounds capable of specifically interacting with the H2BH protein. The identification of these sites would be greatly facilitated by structural determination techniques such as X-ray crystallography, NMR spectroscopy, or cryo-electron microscopy, which could provide a detailed three-dimensional view of H2BH within the nucleosome. Following the structural analysis, various in vitro biochemical assays would be essential to test the interaction between potential activators and H2BH. These assays could include experiments designed to measure changes in nucleosome assembly, to assess the strength of the interaction between H2BH and DNA, or to observe any resultant alterations in chromatin structure. In sum, these investigations would contribute to a deeper understanding of the molecular mechanisms governing chromatin dynamics and the specific role of histone variants such as H2BH.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Panobinostat is an HDAC inhibitor that may upregulate histone acetylation, potentially increasing histone expression. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $214.00 $247.00 $1463.00 | 2 | |
Mocetinostat is an HDAC inhibitor that could influence histone acetylation levels and thereby affect histone gene expression. | ||||||
Chidamide | 743420-02-2 | sc-364462 sc-364462A sc-364462B | 1 mg 5 mg 25 mg | $62.00 $250.00 $1196.00 | ||
Chidamide is an HDAC inhibitor that can modulate histone acetylation, potentially impacting the expression of histone genes. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
Entinostat is an HDAC inhibitor that may alter chromatin structure and affect histone gene expression by changing acetylation patterns. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
Tazemetostat inhibits EZH2, a histone methyltransferase, which might result in altered histone methylation and gene expression. | ||||||
UNC0638 | 1255580-76-7 | sc-397012 | 10 mg | $315.00 | ||
UNC0638 is a selective inhibitor of G9a and GLP histone methyltransferases, potentially affecting histone methylation and gene expression. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
C646 is a competitive inhibitor of HATs, which might lead to reduced histone acetylation and influence gene expression profiles. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 is a BET bromodomain inhibitor that might impact transcription and potentially influence histone gene expression. | ||||||
GSK343 | 1346704-33-3 | sc-397025 sc-397025A | 5 mg 25 mg | $151.00 $461.00 | 1 | |
GSK343 is an EZH2 inhibitor that may result in changes to histone methylation patterns and possibly influence histone gene expression. | ||||||